目的:探讨良性前列腺增生症（benign prostatic hyperplasia，BPH）应用单极电切（TURP）经尿道前列腺剜除术的方法及疗效。方法：应用普通单极电切设备，采用经尿道前列腺剜除术治疗良性前列腺增生症患者21例。并对患者术前、术后的国际前列腺症状评分、生活质量评分进行比较。结果：全部患者均顺利完成手术，切除前列腺重量平均45 g，平均手术时间90 min，术后平均留置导尿管5~7天，术后平均住院时间5.5天。术后前列腺症状评分（IPSS）平均减少24分，生活质量评分平均减少3分。结论：经尿道单极电切前列腺剜除术治疗BPH安全、有效、并发症少，所需设备价格较低，特别适合基层医院开展，是一种值得推广的方法。
目的 比较经尿道前列腺剜除术（TUEP）与经尿道前列腺电切术（TURP）的疗效。 方法 2010年11月－2011年3月，收治前列腺增生（BPH）患者58例，分别采用TUEP（30例）、TURP（28例）治疗。患者年龄55～87岁，平均73岁；病程1～12年，平均5年。术前常规行直肠指检前列腺光滑无结节；经直肠前列腺彩色超声多普勒检查，测得前列腺体积为50～80 mL，平均62 mL；血清前列腺特异性抗原＜10 ng/mL。 结果 TUEP组术中出血量、术后冲洗时间均短于TURP，切除前列腺组织体积大于TURP组，差异均有统计学意义（P＜0.05）。术后拔除尿管后发生暂时性尿失禁TUEP组1例，TURP组发生2例，两组比较差异无统计学意义；两组均无永久性尿失禁发生。 结论 TUEP与TURP相比较，TUEP手术疗效好，出血少、恢复快，且并发症少。
【摘要】 目的 探讨良性前列腺增生症（benign prostatic hyperplasia，BPH）应用经尿道前列腺普通电切镜剜除术（transurethral electro enucleation of the prostate，TUEP）的方法及疗效。 方法 2007年12月－2010年7月，应用TUEP治疗BPH患者201例，并根据前列腺腺体的大小及形状的不同采用不同的剜除方法以提高手术的成功率。 结果 全部患者均顺利完成手术，切除前列腺重量平均38 g，平均手术时间100 min，术后平均留置导尿管时间5~7 d，术后平均住院时间5.5 d。 结论 TUEP是治疗良性前列腺增生症的一种有效方法。【Abstract】 Objective To evaluate the therapeutic effect of transurethral enucleation of prostate on benign prostatic hyperplasisa. Methods From December 2007 to July 2010, 201 patients with benign prostatic hyperplasia underwent transurethral enucleation. According to the size and shape of the gland, different enucleation ways were used to improve the surgical success rate. Results All of the enucleations were successful. The average weight of the resected prostate was 38 grams, the mean operation duration was 100 minutes, the average days of indwelling catheter was 5-7 days, and the average hospital staying was 5.5 days. Conclusion Transurethral enucleation of prostate for benign prostatic hyperplasia is effective.
【摘要】 目的 探讨经尿道超脉冲等离子体腔内逆行剜除汽化切除术治疗良性前列腺增生的有效性和安全性。 方法 2008年4月－2009年4月，应用Gyrus超脉冲等离子体行经尿道前列腺腔内逆行剜除汽化切除术124例，前列腺重量为（62.3±21.7） g。术中首先用电切镜鞘、电切环钝锐性相结合将前列腺增生腺体沿外科包膜逆行剥离、剜除，同时断血供，然后推至膀胱颈处后切除。统计手术时间、术中出血量及收集到的前列腺组织质量，术后留置尿管时间、住院时间、手术后前列腺特异性抗原（prostatic specific antigen，PSA）、残余尿量（post voiding residual volume，PVR）、最大尿流率（Qmax）、国际前列腺症状评分（international prostatic symptom scores，IPSS）及生活质量评分（quality of life，QOL）等指标的变化。 结果 124例手术顺利完成。手术时间（48.1±19.4） min，腺体组织质量（57.6±19.6） g，平均失血量（86.2±20.7） mL，仅1例需要输血，出血量和手术时间随前列腺体积和重量的增加而相应增加和延长。术后留置尿管时间（3.1±1.6） d，住院时间（5.8±1.4） d。随访6～18个月，所有患者术后1、6个月Qmax、PVR、IPSS、QOL均较术前得到改善，与术前比较差异均有统计学意义（Plt;0.05）。术后6个月血清PSA降至（0.90±0.26） ng/mL，与术前比较差异有统计学意义（Plt;0.05）。继发尿道外口狭窄3例，经尿道扩张治疗后恢复排尿通畅；继发尿失禁2例，经保守治疗分别于术后1～6个月恢复；无永久性尿失禁、再次手术止血患者，无手术死亡者，未发生经尿道前列腺电切综合征。 结论 经尿道超脉冲等离子体腔内逆行剜除汽化切除术治疗良性前列腺增生安全有效，值得临床推广使用。【Abstract】 Objective To evaluate the safety and clinical efficacy of superpulse plasmakinetic body in transurethral intracavitary retrograde enucleation and vaporization resection of the prostate (TUEVRP) for the treatment of benign prostatic hyperplasia (BPH). Methods Between April 2008 and April 2009, Gyrus TUEVRP was performed on 124 patients with obstructive BPH whose mean prostatic weight was (62.3±21.7) g. The hyperplasia prostate glands were retrogradely dissected and enucleated along surgical capsule to the bladder neck by sharp and blunt dissection combination of the resectoscope tip or loop. Simultaneously, the blood supply of the gland was clamped. The changes of such indexes as operating time, perioperative blood loss, collected prostatic specimen weight, postoperative catheterization time, hospitalization time, prostatic specific antigen (PSA), post voiding residual volume (PVR), maximum urinary flow rate (Qmax), international prostatic symptom score (IPSS), and quality of life (QOL) were assessed. Results All surgeries were successfully carried out with an average operation time of (48.1±19.4) minutes ranged from 25 to 175 minutes. The mean collected prostatic specimen weight was (57.6±19.6) g ranged from 20.2 to 125.7 g. The blood loss was ranged from 45 to 350 ml, averaging at (86.2±20.7) mL during the operation. Blood transfusion was needed in only one case. Blood loss and operation time were increased and prolonged in accordance with the increase of prostatic volume and weight. The postoperative catheterization time was ranged from 2 to 5 days, averaging at 3.1±1.6. The mean hospitalization time was (5.8±1.4) days ranged from 5 to 8 days. All patients were followed up for 6 to 18 months. Qmax, PVR, IPSS and QOL-score six months after operation were significantly improved compared with those before operation (Plt;0.05). There were three cases of external urethral stricture, and they were treated with urethral dilatation successfully. Two cases of urinary incontinence recovered 1 and 6 months later, respectively, by traditional treatment. There were no cases of permanent urinary incontinence, reoperation for hemostasis, operative death, or transurethral resection syndrome. Conclusion TUEVRP is safe and clinically efficacious in the treatment of BPH, and is worthy of clinical promotion.